<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Novel biomarkers predicting <z:hpo ids='HP_0003674'>onset</z:hpo> or progression of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> in patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> have been recently identified </plain></SENT>
<SENT sid="1" pm="."><plain>We performed a systematic review to assess the validity of biomarkers predicting <z:hpo ids='HP_0003674'>onset</z:hpo> or progression of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> in patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in longitudinal studies </plain></SENT>
<SENT sid="2" pm="."><plain>The methodological quality of the studies was scored using Standards for Reporting of Diagnostic Accuracy (STARD) criteria and the independent predictive value of the biomarkers beyond conventional risk factors was scored according to the adjustment for these risk factors </plain></SENT>
<SENT sid="3" pm="."><plain>Validity of the biomarkers was determined by summarizing the methodological quality and the adjustment score </plain></SENT>
<SENT sid="4" pm="."><plain>We identified 15 studies describing 27 biomarkers </plain></SENT>
<SENT sid="5" pm="."><plain>Six studies had sufficient methodological quality </plain></SENT>
<SENT sid="6" pm="."><plain>These studies identified 13 valid and significant markers for <z:hpo ids='HP_0000112'>nephropathy</z:hpo> in <z:mp ids='MP_0002055'>diabetes</z:mp>: serum interleukin 18, plasma asymmetric dimethylarginine; and urinary ceruloplasmin, immunoglobulin G and transferrin were considered valid markers predicting <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Plasma asymmetric dimethylarginine, vascular cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule 1, interleukin 6, <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor and intercellular cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule 1 were considered valid biomarkers predicting progression of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Plasma high-sensitivity C-reactive protein, E-selectin, tissue-type plasminogen activator, <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor and <z:chebi fb="4" ids="17855">triglycerides</z:chebi> were considered valid markers predicting <z:hpo ids='HP_0003674'>onset</z:hpo> and progression of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Several novel biomarkers for prediction of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> in <z:mp ids='MP_0002055'>diabetes</z:mp> have been published, which can potentially be applied in clinical practice and research in future </plain></SENT>
<SENT sid="10" pm="."><plain>Because of the <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> quality of biomarker studies in this field, a more rigorous evaluation of these biomarkers and validation in larger trials are advocated </plain></SENT>
</text></document>